卡培他滨联合替莫唑胺治疗晚期胰腺神经内分泌肿瘤的临床观察

  目的  观察卡培他滨联合替莫唑胺治疗晚期胰腺神经内分泌肿瘤（pancreatic neuroendocrine neoplasm，pNENs）的疗效及不良反应。  方法  回顾性分析2014年2月至2016年10月中日友好医院收治的14例经病理学确诊，分化良好的Ⅳ期pNENs患者，接受口服CAPTEM方案，分析治疗后的无进展生存期（progression free survival，PFS）及不良反应。  结果  14例患者接受定期随访2年余（2014年1月至2016年10月），1例完全缓解（complete resporse，CR），1例部分缓解（partial response，PR），4例疾病稳定（stable disease，SD），中位无进展生存期（median progression free survival，mPFS）约为8.9（3~24）个月，2年生存率为85.7%（12/14），其中不良反应均为3级以下的骨髓抑制、消化道反应。  结论  卡培他滨联合替莫唑胺（capecitabine and temozolomide，CAPTEM）方案是治疗晚期胰腺神经内分泌瘤（pancreatic neuroendocrine tumor，pNET）的有效化疗方案，患者耐受性较好。 

Clinical observation of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors

Objective:To observe the therapeutic effect and toxicity of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors. Methods:A total of 14 patients with stageⅣwell-differentiated pancreatic neuroendocrine tumor (NET G1/G2/G3) were treated with oral CAPTEM regimen, and the response rate, PFS and adverse effect after treatment were analyzed. All data analyses were performed using software SPSS17.0. Results:These 14 patients were followed-up for more than 2 years. Till Oct 2016, one patient got CR, one patient got PR, four patients got SD. Median progression-free survival was 8.9 months. The two year survival rate was 85.7%. Only one patient experienced grade 3 adverse events. Conclusion:CAPTEM is an effective and well-tolerated salvage regimen for the treatment of advanced well-differentiated pNET.